Baseline characteristics and prevalence of thyroid dysfunction by time of blood sampling.
| . | 00.01–06.00 N = 360 . | 06.01–12:00 N = 570 . | 12:01–18.00 N = 570 . | 18.01–00.00 N = 419 . | P value . |
|---|---|---|---|---|---|
| Age, mean (± SD), years | 63.7 ± 12.3 | 64.5 ± 12.4 | 64.9 ± 11.7 | 62.9 ± 11.8 | .06 |
| Females, n (%) | 108 (30.0) | 175 (30.7) | 160 (28.1) | 118 (28.2) | .73 |
| Current smokers, n (%) | 128 (35.6) | 164 (28.8) | 161 (28.2) | 143 (34.3) | .07 |
| BMI, mean (± SD), kg/m2 | 28.4 ± 5.7 | 28.2 ± 5.1 | 28.6 ± 5.6 | 28.9 ± 5.7 | .22 |
| STEMI, n (%) | 191 (53.1) | 288 (50.5) | 252 (44.2) | 204 (48.7) | .04 |
| Pulse rate, mean (±SD), beats/minute | 76.8 ± 16.9 | 76.8 ± 17.4 | 75.4 ± 17.3 | 76.7 ± 19.2 | .75 |
| Blood pressure, mean (±SD), mm Hg | |||||
| Systolic | 136.2 ± 29.1 | 138.8 ± 27.2 | 139.6 ± 24.4 | 139.6 ± 27.7 | .54 |
| Diastolic | 80.2 ± 16.7 | 80.6 ± 17.0 | 80.6 ± 15.9 | 82.4 ± 17.2 | .55 |
| Pain to sampling time, median (IQR), minutesa | 165 (88–232) | 128 (42–183) | 136 (57–202) | 161 (97–209) | .38 |
| Coronary artery affected, n (%) | |||||
| Left main stem | 6 | 11 | 9 | 9 | |
| Left anterior descending | 142 | 218 | 221 | 158 | .34 |
| Right coronary | 161 | 267 | 264 | 191 | |
| Circumflex | 49 | 71 | 76 | 59 | |
| Graft | 2 | 3 | 0 | 2 | |
| Thyrotropin, median (IQR), mU/L | 2.60 (1.50–4.23) | 1.93 (1.31–2.93) | 1.80 (1.16–2.74) | 2.10 (1.36–3.60) | <.001 |
| Free thyroxine (FT4), mean (± SD), pmol/L | 16.4 ± 3.4 | 16.3 ± 4.1 | 16.1 ± 3.2 | 16.4 ± 3.9 | .43 |
| Free triiodothyronine (FT3), mean (± SD), pmol/L | 4.9 ± 1.0 | 4.7 ± 0.8 | 4.6 ± 0.7 | 4.7 ± 0.9 | <.001 |
| Thyroid status, n (%)b | |||||
| Euthyroid | 242 (72.2) | 450 (84.4) | 465 (85.5) | 313 (79.4) | |
| SCH | 92 (27.5) | 79 (14.8) | 65 (12.0) | 77 (19.6) | <.001 |
| SHyper | 1 (0.3) | 4 (0.8) | 14 (2.6) | 4 (1.0) | |
| TPOAb, median (IQR), (U/L) | 13.3 (8.8–28) | 12.1 (9.2–28) | 12.7 (9.3–28) | 11.9 (9.3–28) | .84 |
| TPOAb positive, n (%) | 65 (18.0) | 94 (16.4) | 95 (16.7) | 61 (14.5) | .77 |
| Creatinine, mean (± SD), μmol/L | 92.3 ± 39.8 | 90.8 ± 51.3 | 90.8 ± 38.3 | 88.9 ± 28.2 | .74 |
| Past medical history, n (%) | |||||
| Treated hypothyroidism | 25 (6.9) | 36 (6.3) | 27 (4.7) | 25 (6.0) | .52 |
| Ischemic heart disease | 91 (25.3) | 162 (28.4) | 156 (27.4) | 93 (22.2) | .14 |
| Hypertension | 137 (38.1) | 243 (42.6) | 246 (43.2) | 158 (37.7) | .18 |
| Atrial fibrillation | 17 (4.7) | 25 (4.4) | 20 (3.5) | 16 (3.8) | .79 |
| Type 2 diabetes mellitus | 65 (18.1) | 114 (20.0) | 92 (16.1) | 68 (16.2) | .29 |
| Cerebrovascular disease | 15 (4.2) | 27 (4.7) | 38 (6.7) | 15 (3.6) | .12 |
| Peripheral vascular disease | 16 (4.7) | 10 (1.9) | 20 (3.7) | 15 (3.8) | .13 |
| . | 00.01–06.00 N = 360 . | 06.01–12:00 N = 570 . | 12:01–18.00 N = 570 . | 18.01–00.00 N = 419 . | P value . |
|---|---|---|---|---|---|
| Age, mean (± SD), years | 63.7 ± 12.3 | 64.5 ± 12.4 | 64.9 ± 11.7 | 62.9 ± 11.8 | .06 |
| Females, n (%) | 108 (30.0) | 175 (30.7) | 160 (28.1) | 118 (28.2) | .73 |
| Current smokers, n (%) | 128 (35.6) | 164 (28.8) | 161 (28.2) | 143 (34.3) | .07 |
| BMI, mean (± SD), kg/m2 | 28.4 ± 5.7 | 28.2 ± 5.1 | 28.6 ± 5.6 | 28.9 ± 5.7 | .22 |
| STEMI, n (%) | 191 (53.1) | 288 (50.5) | 252 (44.2) | 204 (48.7) | .04 |
| Pulse rate, mean (±SD), beats/minute | 76.8 ± 16.9 | 76.8 ± 17.4 | 75.4 ± 17.3 | 76.7 ± 19.2 | .75 |
| Blood pressure, mean (±SD), mm Hg | |||||
| Systolic | 136.2 ± 29.1 | 138.8 ± 27.2 | 139.6 ± 24.4 | 139.6 ± 27.7 | .54 |
| Diastolic | 80.2 ± 16.7 | 80.6 ± 17.0 | 80.6 ± 15.9 | 82.4 ± 17.2 | .55 |
| Pain to sampling time, median (IQR), minutesa | 165 (88–232) | 128 (42–183) | 136 (57–202) | 161 (97–209) | .38 |
| Coronary artery affected, n (%) | |||||
| Left main stem | 6 | 11 | 9 | 9 | |
| Left anterior descending | 142 | 218 | 221 | 158 | .34 |
| Right coronary | 161 | 267 | 264 | 191 | |
| Circumflex | 49 | 71 | 76 | 59 | |
| Graft | 2 | 3 | 0 | 2 | |
| Thyrotropin, median (IQR), mU/L | 2.60 (1.50–4.23) | 1.93 (1.31–2.93) | 1.80 (1.16–2.74) | 2.10 (1.36–3.60) | <.001 |
| Free thyroxine (FT4), mean (± SD), pmol/L | 16.4 ± 3.4 | 16.3 ± 4.1 | 16.1 ± 3.2 | 16.4 ± 3.9 | .43 |
| Free triiodothyronine (FT3), mean (± SD), pmol/L | 4.9 ± 1.0 | 4.7 ± 0.8 | 4.6 ± 0.7 | 4.7 ± 0.9 | <.001 |
| Thyroid status, n (%)b | |||||
| Euthyroid | 242 (72.2) | 450 (84.4) | 465 (85.5) | 313 (79.4) | |
| SCH | 92 (27.5) | 79 (14.8) | 65 (12.0) | 77 (19.6) | <.001 |
| SHyper | 1 (0.3) | 4 (0.8) | 14 (2.6) | 4 (1.0) | |
| TPOAb, median (IQR), (U/L) | 13.3 (8.8–28) | 12.1 (9.2–28) | 12.7 (9.3–28) | 11.9 (9.3–28) | .84 |
| TPOAb positive, n (%) | 65 (18.0) | 94 (16.4) | 95 (16.7) | 61 (14.5) | .77 |
| Creatinine, mean (± SD), μmol/L | 92.3 ± 39.8 | 90.8 ± 51.3 | 90.8 ± 38.3 | 88.9 ± 28.2 | .74 |
| Past medical history, n (%) | |||||
| Treated hypothyroidism | 25 (6.9) | 36 (6.3) | 27 (4.7) | 25 (6.0) | .52 |
| Ischemic heart disease | 91 (25.3) | 162 (28.4) | 156 (27.4) | 93 (22.2) | .14 |
| Hypertension | 137 (38.1) | 243 (42.6) | 246 (43.2) | 158 (37.7) | .18 |
| Atrial fibrillation | 17 (4.7) | 25 (4.4) | 20 (3.5) | 16 (3.8) | .79 |
| Type 2 diabetes mellitus | 65 (18.1) | 114 (20.0) | 92 (16.1) | 68 (16.2) | .29 |
| Cerebrovascular disease | 15 (4.2) | 27 (4.7) | 38 (6.7) | 15 (3.6) | .12 |
| Peripheral vascular disease | 16 (4.7) | 10 (1.9) | 20 (3.7) | 15 (3.8) | .13 |
aCalculated as the length of time from onset of pain till blood sample obtained.
bAfter excluding individuals on levothyroxine therapy; therefore, total numbers do not add up to the sample size for the whole group for each time period.
Means compared using analysis of variance.
Medians compared using Kruskal–Wallis test.
Proportions compared using chi square test.
Abbreviations: BMI, body mass index; STEMI, ST-elevation myocardial infarction; SCH, subclinical hypothyroidism; SHyper, subclinical hyperthyroidism; TPOAb, thyroid peroxidase antibody.
Baseline characteristics and prevalence of thyroid dysfunction by time of blood sampling.
| . | 00.01–06.00 N = 360 . | 06.01–12:00 N = 570 . | 12:01–18.00 N = 570 . | 18.01–00.00 N = 419 . | P value . |
|---|---|---|---|---|---|
| Age, mean (± SD), years | 63.7 ± 12.3 | 64.5 ± 12.4 | 64.9 ± 11.7 | 62.9 ± 11.8 | .06 |
| Females, n (%) | 108 (30.0) | 175 (30.7) | 160 (28.1) | 118 (28.2) | .73 |
| Current smokers, n (%) | 128 (35.6) | 164 (28.8) | 161 (28.2) | 143 (34.3) | .07 |
| BMI, mean (± SD), kg/m2 | 28.4 ± 5.7 | 28.2 ± 5.1 | 28.6 ± 5.6 | 28.9 ± 5.7 | .22 |
| STEMI, n (%) | 191 (53.1) | 288 (50.5) | 252 (44.2) | 204 (48.7) | .04 |
| Pulse rate, mean (±SD), beats/minute | 76.8 ± 16.9 | 76.8 ± 17.4 | 75.4 ± 17.3 | 76.7 ± 19.2 | .75 |
| Blood pressure, mean (±SD), mm Hg | |||||
| Systolic | 136.2 ± 29.1 | 138.8 ± 27.2 | 139.6 ± 24.4 | 139.6 ± 27.7 | .54 |
| Diastolic | 80.2 ± 16.7 | 80.6 ± 17.0 | 80.6 ± 15.9 | 82.4 ± 17.2 | .55 |
| Pain to sampling time, median (IQR), minutesa | 165 (88–232) | 128 (42–183) | 136 (57–202) | 161 (97–209) | .38 |
| Coronary artery affected, n (%) | |||||
| Left main stem | 6 | 11 | 9 | 9 | |
| Left anterior descending | 142 | 218 | 221 | 158 | .34 |
| Right coronary | 161 | 267 | 264 | 191 | |
| Circumflex | 49 | 71 | 76 | 59 | |
| Graft | 2 | 3 | 0 | 2 | |
| Thyrotropin, median (IQR), mU/L | 2.60 (1.50–4.23) | 1.93 (1.31–2.93) | 1.80 (1.16–2.74) | 2.10 (1.36–3.60) | <.001 |
| Free thyroxine (FT4), mean (± SD), pmol/L | 16.4 ± 3.4 | 16.3 ± 4.1 | 16.1 ± 3.2 | 16.4 ± 3.9 | .43 |
| Free triiodothyronine (FT3), mean (± SD), pmol/L | 4.9 ± 1.0 | 4.7 ± 0.8 | 4.6 ± 0.7 | 4.7 ± 0.9 | <.001 |
| Thyroid status, n (%)b | |||||
| Euthyroid | 242 (72.2) | 450 (84.4) | 465 (85.5) | 313 (79.4) | |
| SCH | 92 (27.5) | 79 (14.8) | 65 (12.0) | 77 (19.6) | <.001 |
| SHyper | 1 (0.3) | 4 (0.8) | 14 (2.6) | 4 (1.0) | |
| TPOAb, median (IQR), (U/L) | 13.3 (8.8–28) | 12.1 (9.2–28) | 12.7 (9.3–28) | 11.9 (9.3–28) | .84 |
| TPOAb positive, n (%) | 65 (18.0) | 94 (16.4) | 95 (16.7) | 61 (14.5) | .77 |
| Creatinine, mean (± SD), μmol/L | 92.3 ± 39.8 | 90.8 ± 51.3 | 90.8 ± 38.3 | 88.9 ± 28.2 | .74 |
| Past medical history, n (%) | |||||
| Treated hypothyroidism | 25 (6.9) | 36 (6.3) | 27 (4.7) | 25 (6.0) | .52 |
| Ischemic heart disease | 91 (25.3) | 162 (28.4) | 156 (27.4) | 93 (22.2) | .14 |
| Hypertension | 137 (38.1) | 243 (42.6) | 246 (43.2) | 158 (37.7) | .18 |
| Atrial fibrillation | 17 (4.7) | 25 (4.4) | 20 (3.5) | 16 (3.8) | .79 |
| Type 2 diabetes mellitus | 65 (18.1) | 114 (20.0) | 92 (16.1) | 68 (16.2) | .29 |
| Cerebrovascular disease | 15 (4.2) | 27 (4.7) | 38 (6.7) | 15 (3.6) | .12 |
| Peripheral vascular disease | 16 (4.7) | 10 (1.9) | 20 (3.7) | 15 (3.8) | .13 |
| . | 00.01–06.00 N = 360 . | 06.01–12:00 N = 570 . | 12:01–18.00 N = 570 . | 18.01–00.00 N = 419 . | P value . |
|---|---|---|---|---|---|
| Age, mean (± SD), years | 63.7 ± 12.3 | 64.5 ± 12.4 | 64.9 ± 11.7 | 62.9 ± 11.8 | .06 |
| Females, n (%) | 108 (30.0) | 175 (30.7) | 160 (28.1) | 118 (28.2) | .73 |
| Current smokers, n (%) | 128 (35.6) | 164 (28.8) | 161 (28.2) | 143 (34.3) | .07 |
| BMI, mean (± SD), kg/m2 | 28.4 ± 5.7 | 28.2 ± 5.1 | 28.6 ± 5.6 | 28.9 ± 5.7 | .22 |
| STEMI, n (%) | 191 (53.1) | 288 (50.5) | 252 (44.2) | 204 (48.7) | .04 |
| Pulse rate, mean (±SD), beats/minute | 76.8 ± 16.9 | 76.8 ± 17.4 | 75.4 ± 17.3 | 76.7 ± 19.2 | .75 |
| Blood pressure, mean (±SD), mm Hg | |||||
| Systolic | 136.2 ± 29.1 | 138.8 ± 27.2 | 139.6 ± 24.4 | 139.6 ± 27.7 | .54 |
| Diastolic | 80.2 ± 16.7 | 80.6 ± 17.0 | 80.6 ± 15.9 | 82.4 ± 17.2 | .55 |
| Pain to sampling time, median (IQR), minutesa | 165 (88–232) | 128 (42–183) | 136 (57–202) | 161 (97–209) | .38 |
| Coronary artery affected, n (%) | |||||
| Left main stem | 6 | 11 | 9 | 9 | |
| Left anterior descending | 142 | 218 | 221 | 158 | .34 |
| Right coronary | 161 | 267 | 264 | 191 | |
| Circumflex | 49 | 71 | 76 | 59 | |
| Graft | 2 | 3 | 0 | 2 | |
| Thyrotropin, median (IQR), mU/L | 2.60 (1.50–4.23) | 1.93 (1.31–2.93) | 1.80 (1.16–2.74) | 2.10 (1.36–3.60) | <.001 |
| Free thyroxine (FT4), mean (± SD), pmol/L | 16.4 ± 3.4 | 16.3 ± 4.1 | 16.1 ± 3.2 | 16.4 ± 3.9 | .43 |
| Free triiodothyronine (FT3), mean (± SD), pmol/L | 4.9 ± 1.0 | 4.7 ± 0.8 | 4.6 ± 0.7 | 4.7 ± 0.9 | <.001 |
| Thyroid status, n (%)b | |||||
| Euthyroid | 242 (72.2) | 450 (84.4) | 465 (85.5) | 313 (79.4) | |
| SCH | 92 (27.5) | 79 (14.8) | 65 (12.0) | 77 (19.6) | <.001 |
| SHyper | 1 (0.3) | 4 (0.8) | 14 (2.6) | 4 (1.0) | |
| TPOAb, median (IQR), (U/L) | 13.3 (8.8–28) | 12.1 (9.2–28) | 12.7 (9.3–28) | 11.9 (9.3–28) | .84 |
| TPOAb positive, n (%) | 65 (18.0) | 94 (16.4) | 95 (16.7) | 61 (14.5) | .77 |
| Creatinine, mean (± SD), μmol/L | 92.3 ± 39.8 | 90.8 ± 51.3 | 90.8 ± 38.3 | 88.9 ± 28.2 | .74 |
| Past medical history, n (%) | |||||
| Treated hypothyroidism | 25 (6.9) | 36 (6.3) | 27 (4.7) | 25 (6.0) | .52 |
| Ischemic heart disease | 91 (25.3) | 162 (28.4) | 156 (27.4) | 93 (22.2) | .14 |
| Hypertension | 137 (38.1) | 243 (42.6) | 246 (43.2) | 158 (37.7) | .18 |
| Atrial fibrillation | 17 (4.7) | 25 (4.4) | 20 (3.5) | 16 (3.8) | .79 |
| Type 2 diabetes mellitus | 65 (18.1) | 114 (20.0) | 92 (16.1) | 68 (16.2) | .29 |
| Cerebrovascular disease | 15 (4.2) | 27 (4.7) | 38 (6.7) | 15 (3.6) | .12 |
| Peripheral vascular disease | 16 (4.7) | 10 (1.9) | 20 (3.7) | 15 (3.8) | .13 |
aCalculated as the length of time from onset of pain till blood sample obtained.
bAfter excluding individuals on levothyroxine therapy; therefore, total numbers do not add up to the sample size for the whole group for each time period.
Means compared using analysis of variance.
Medians compared using Kruskal–Wallis test.
Proportions compared using chi square test.
Abbreviations: BMI, body mass index; STEMI, ST-elevation myocardial infarction; SCH, subclinical hypothyroidism; SHyper, subclinical hyperthyroidism; TPOAb, thyroid peroxidase antibody.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
